World Investment Advisors Acquires 2,109 Shares of Elevance Health, Inc. $ELV

World Investment Advisors raised its holdings in Elevance Health, Inc. (NYSE:ELV) by 7.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 30,399 shares of the company’s stock after acquiring an additional 2,109 shares during the quarter. World Investment Advisors’ holdings in Elevance Health were worth $8,899,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Kemnay Advisory Services Inc. bought a new position in shares of Elevance Health in the fourth quarter worth approximately $31,000. J.Safra Asset Management Corp bought a new stake in Elevance Health during the fourth quarter valued at approximately $32,000. ORG Partners LLC lifted its position in Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Elevance Health in the 4th quarter worth approximately $38,000. Finally, Dorato Capital Management purchased a new position in Elevance Health in the 4th quarter worth approximately $41,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV opened at $416.97 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock’s 50 day simple moving average is $391.29 and its 200 day simple moving average is $351.14. The firm has a market cap of $90.55 billion, a price-to-earnings ratio of 17.74, a PEG ratio of 2.37 and a beta of 0.67. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $427.19.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, analysts predict that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Mizuho increased their target price on Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Evercore reaffirmed a “hold” rating on shares of Elevance Health in a research note on Tuesday, May 19th. The Goldman Sachs Group upped their price objective on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. UBS Group increased their price objective on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Finally, Barclays raised their price objective on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $419.16.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.34% of the stock is currently owned by company insiders.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.